Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

Abstract Objective Crizotinib can target against mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK), which has been considered as a multi-targeted tyrosine kinase inhibitor (TKI). The objective of this study was to explore the efficacy of crizotinib in advanced non-small-ce...

Full description

Bibliographic Details
Main Authors: Rui-Lian Chen, Jun Zhao, Xu-Chao Zhang, Na-Na Lou, Hua-Jun Chen, Xue Yang, Jian Su, Zhi Xie, Qing Zhou, Hai-Yan Tu, Wen-Zhao Zhong, Hong-Hong Yan, Wei-Bang Guo, Yi-Long Wu, Jin-Ji Yang
Format: Article
Language:English
Published: BMC 2018-11-01
Series:BMC Cancer
Subjects:
Anaplastic lymphoma kinase
Mesenchymal epithelial transition
Non-small-cell lung cancer
Rearrangement
C-Met, overexpression
Online Access:http://link.springer.com/article/10.1186/s12885-018-5078-y

Internet

http://link.springer.com/article/10.1186/s12885-018-5078-y

Similar Items